Feature | Atrial Fibrillation | December 18, 2017| Kenneth Stein, M.D. FACC FHRS

Meeting the Treatment Demands of a Growing AFib Epidemic

EP mapping systems to guide catheter ablations have become more precise with high-density electromapping

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

The Apama single-shot ablation balloon pulmonary vein isolation for atrial fibrillation

The Apama single-shot ablation balloon pulmonary vein isolation for atrial fibrillation

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System offers higher-density voltage maps that previous generation EP mapping systems.

When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation to restore a normal rhythm to patients with atrial fibrillation (AFib) in a lab setting was just that: a dream.[1] Today, nearly 6 million Americans live with AFib, and that number is expected to nearly double by 2030.[2,3]  I have been fortunate in my career to witness the introduction and aid in the design of novel technologies to meet the treatment demands created by the surge of AFib diagnoses. But there is more that must be done to improve our ability to detect and map rhythm abnormalities. At Boston Scientific, we are more motivated than ever to close that gap and improve treatment for those living with heart rhythm disorders.  

 

Where We Have Been in Cardiac Mapping 

Electroanatomical mapping has come a long way in the last 70 years. Early technology was simple, with each device performing only a single task. In the 1950s, physicians and researchers were learning how to record heart rhythms with electrocardiograms to locate arrhythmias.[4,5] In the 1970s, catheter-based imaging and 2-D ultrasound images helped better visualize heart anatomy, but pinpointing the precise location of the rhythm abnormality remained a challenge.[6,7] It was a shift to increasing usage of catheter ablation over other treatment options in the 1980s that led to the advent of combined mapping and navigation.[8,9]

 

In the 1990s, new 3-D systems provided more accurate data by showing heart anatomy and electrical activity together, enabling catheter localization in real time.[10-13] These advances were particularly valuable for patients with complex arrhythmias or complicated cardiac anatomy.[14] Our vision of the heart and its rhythms improved from 20/100 to 20/40 — better than before, but still not perfect. 

 

 

Where We Are Heading in Cardiac Mapping to Meet the Needs of Physicians

The 21st century launched us into a new era for cardiac mapping, with technological advances now emphasizing visualization in high definition and treatment with high precision. The hardware and software of new mapping systems are being designed in concert, allowing the mapping procedure to be better coordinated and automated. Unlike previous systems, the Boston Scientific Rhythmia HDx Mapping System rapidly and automatically generates 3-D maps of any chamber of the heart to help locate and treat the source of rhythm abnormality. The technology allows electrophysiologists to see the heart like never before, with 20/20 or better vision.

 

A recent analysis of patients with symptomatic AFib showed that compared to other mapping systems, the Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.[15] In fact, the technology has the ability to automatically map the heart with a speed that allows physicians greater efficiency in the EP lab and thus, more time to develop a well-informed ablation strategy. 

 

In addition, the use of complementary technologies helps improves connectivity between the system, catheters and ablation devices, streamlining workflow in the EP lab. For example, while still an investigational device, we acquired the Apama Medical Radiofrequency Balloon Catheter System (not yet available for sale) because its design offers the benefits of point-by-point and balloon-based ablation technologies without increasing procedure times. Our goal is for the catheter to work in connection with the mapping system for faster data collection and better procedural outcomes benefiting EP lab workflow and ultimately, patients. 

 

We are at a pivotal point in the evolution of electroanatomical mapping, and I am in awe of how modern technology has advanced medicine. With the current momentum driving us forward, the goal is to continue to advance patient-focused solutions to a place where we can meet the needs of our patients safely, effectively, predictably and precisely.  

 

Editor’s note: Kenneth Stein, M.D. FACC FHRS, is the senior vice president and chief medical officer for rhythm management and global health policy at Boston Scientific. Prior to joining Boston Scientific in 2009, Stein was associate director of clinical cardiac electrophysiology at Weill Cornell Medical Center and associate professor of medicine at Cornell University. He has published widely in the areas of cardiac electrophysiology with a special interest in cardiac resynchronization therapy and risk stratification for sudden cardiac arrest.

 

 

 

Related Content on Atrial Fibrfillation Technology Advances:

New Data and Technology To Treat Atrial Fibrillation

VIDEO: Current State of Atrial Fibrillation Ablation Technologies —Interview with Hugh Calkins, M.D.

 

 

References: 

1. Jais, P., Sanders, P., Hsu, L. F., Hocini, M., & Haissaguerre, M. (2005). Catheter ablation for atrial fibrillation. Heart, 91(1), 7–9. http://doi.org/10.1136/hrt.2003.030205

2. Centers for Disease Control and Prevention website. Atrial fibrillation fact sheet. https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. Updated August 22, 2017. Accessed November 16, 2017. 

3. Colilla, Susan et al. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. American Journal of Cardiology , Volume 112 , Issue 8, 1142 – 1147

4. The ECG Library website. http://www.ecglibrary.com/ecghist.html. Updated May 11, 2009. Accessed November 16, 2017.

5. Abrams HL. History of cardiac radiology. AJR Am J Roentgenol. 1996;167(2):431-438

6. Hijazi ZM, Shivkumar K, Sahn DJ. Intracardiac electrocardiography (ICE) during interventional & electrophysiological cardiac catheterization. Circulation. 2009;119(4):587-596

7. Maleki, M, Esmaeilzadeh, M. The evolutionary development of echocardiography. Iran J Med Sci. 2012:37(4):222-232

8. Joseph JP, Rajappan K. Radiofrequency ablation of cardiac arrhythmias: past, present and future. QJM. 2012:105(4):303-314

9. University of California San Francisco Cardiology website. History of AF ablation. https://cardiology.ucsf.edu/care/clinical/electro/ablation_hist.html. Accessed November 16, 2017.

10. Gepstein L, Evans SJ. Electroanatomical mapping of the heart: basic concepts and implications for the treatment of cardiac arrhythmias. Pacing Clin Electrophysiol. 1998;21(6):1268-1278.

11. Wittkampf FHM, Wever EFD, Derksen R, et al. LocaLisa-new technique for real-time 3-dimensional localization of regular intracardiac electrodes. Circulation. 1999;99:1312-1317.

12. Endocardial Solutions, Inc. Endocardial Solutions Announces FDA Approval of EnSite NavX [press release]. Published April 22, 2003. http://www.prnewswire.com/news-releases/endocardial-solutions-announces-fda-approval-of-ensite-navxtm-70899022.html. Accessed November 16, 2017.

13. Nakagawa H, Ikeda A, Sharma T, et al. Rapid high resolution electroanatomical mapping: evaluation of a new system in a canine atrial linear lesion model. Circ Arrhythm Electrophysiol. 2012;5(2):417-24.

14. Bhakta D, Miller JM. Principles of electroanatomic mapping. Indian Pacing Electrophysiol J. 2008; 8(1): 32-50. 

15. Rottner L, Metzner A, Ouyang F, et al. Direct comparison of point-by-point and rapid ultra-high-resolution electroanatomical mapping in patients scheduled for ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2017;28(3):289-297.

Related Content

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...
Overlay Init